Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07792954
Recruiting Phase 3

A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity

NCT07792954 · tracked via the Priya Life Science China tracker
Sponsor
Pfizer
Phase
Phase 3
Started
2026-09-24
Last updated
2026-11-05

Condition(s) studied

ObesityOverweight

Investigational drug(s) / intervention(s)

Berobenatide →Placebo

Berobenatide: Solution for injection

Placebo: Solution for injection

Study summary

Overweight and obesity are long-term health conditions that can increase the risk of serious health problems, including heart disease, type 2 diabetes, and other medical conditions.

The purpose of this study is to learn whether berobenatide is safe and effective for adults in China who have overweight or obesity. Researchers will compare berobenatide with a placebo, which looks like the study treatment but does not contain active medicine.

People may be able to participate if they are adults with obesity or if they have overweight together with certain weight-related health conditions. Some participants may also have type 2 diabetes. Specific eligibility requirements will be reviewed by the study doctor before enrollment.

Participants will be randomly assigned to receive either berobenatide or placebo. The study treatment will be administered according to the study protocol, and participants will be monitored throughout the study to assess changes in body weight and overall health, as well as any side effects that may occur.

During participation, participants will attend study visits and complete study-related assessments. Researchers will collect information about participants' health, body weight, and safety throughout the study. Details about the number of visits, study duration, and study procedures will be explained by the study team before participation.

The information learned from this study may help researchers better understand whether berobenatide could be a treatment option for adults living with overweight or obesity.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adults ≥18 years of age. * BMI ≥28 kg/m²; or BMI ≥24 kg/m² and \<28 kg/m² with at least one weight-related comorbidity. * Participants with T2D must have HbA1c 6.5% to 10.0%. * At least one prior unsuccessful dietary weight-loss attempt. Exclusion Criteria: * Significant recent weight change (\>5% within 3 months). * Type 1 diabetes mellitus. * History of pancreatitis. * Personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple endocrine neoplasia type 2 (MEN2). * Recent bariatric surgery or obesity procedures. * Pregnancy or breastfeeding.

Primary outcome measure(s)

  • Percent Change From Baseline in Body Weight at Week 48 — Baseline to Week 48

Trial sites (34)

FacilityCityRegionStatus
The Second People's Hospital of Hefei Hefei Anhui Recruiting
Peking University People's Hospital Beijing Beijing Municipality Recruiting
Beijing Friendship Hospital Beijing Beijing Municipality Recruiting
Beijing Pinggu Hospital Beijing Beijing Municipality Recruiting
Beijing Tsinghua Changgung Hospital Beijing Beijing Municipality Recruiting
Chongqing People's Hospital Chongqing Chongqing Municipality Recruiting
Chongqing University Three Gorges Hospital Chongqing Chongqing Municipality Recruiting
Huizhou Central People's Hospital Huizhou Guangdong Recruiting
Harrison International Peace Hospital Hengshui Hebei Recruiting
The Second Hospital of Hebei Medical University Shijiazhuang Hebei Not Yet Recruiting
The Fourth Hospital of Harbin Medical University Harbin Heilongjiang Recruiting
Luoyang First People's Hospital Luoyang Henan Recruiting
The First Affiliated Hospital of Henan University of Science &Technology Luoyang Henan Recruiting
The Second Affiliated Hospital of Zhengzhou University Zhengzhou Henan Recruiting
Shiyan Taihe Hospital Shiyan Hubei Not Yet Recruiting
Wuhan Third Hospital Wuhan Hubei Recruiting
Changzhou Second People's Hospital Changzhou Jiangsu Recruiting
The Second Affiliated Hospital of Nanjing Medical University Nanjing Jiangsu Recruiting
Nanjing First Hospital Nanjing Jiangsu Recruiting
Affiliated Hospital of Nantong University Nantong Jiangsu Recruiting
Affiliated Hospital of Jiangsu University Zhenjiang Jiangsu Recruiting
Jiangxi Provincial People's Hospital Nanchang Jiangxi Recruiting
Pingxiang People's Hospital Pingxiang Jiangxi Recruiting
The Second Hospital of Jilin University Changchun Jilin Recruiting
The First Affiliated Hospital of Xi'an Medical University Xi'an Shaanxi Recruiting
Jinan Central Hospital Jinan Shandong Recruiting
Zhongshan Hospital,Fudan University Shanghai Shanghai Municipality Recruiting
Shanghai Tenth People's Hospital Shanghai Shanghai Municipality Not Yet Recruiting
The Fifth People's Hospital of Shanghai Shanghai Shanghai Municipality Recruiting
Pudong New Area People's Hospital Shanghai Shanghai Shanghai Municipality Recruiting
Hangzhou First People's Hospital Hangzhou Zhejiang Not Yet Recruiting
Huzhou Central Hospital Huzhou Zhejiang Recruiting
The first affiliated hospital of Ningbo university Ningbo Zhejiang Recruiting
Tianjin Medical University General Hospital Tianjin China Recruiting

More Pfizer trials in China

A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema Recruiting
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments Recruiting
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer Recruiting
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). Active, not recruiting
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC Active, not recruiting

Other trials for the same condition

Probiotic for Weight Management in Overweight and Obese Adults Starting soon
Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin Starting soon
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes Active, not recruiting
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity Recruiting
AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07792954 on ClinicalTrials.gov ↗ ← All trials in China